Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Historical Holders from Q4 2017 to Q3 2025

Symbol: APLS on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 127,672,444
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 122,353,461
Holdings value: $2,771,618,915
% of all portfolios: 0.003%
Number of holders: 269
Number of buys: 150
Number of sells: -120
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
WELLINGTON MANAGEMENT GROUP LLP	10.9%	+52.9%	$311,174,879	+$107,289,396	13,750,547	+52.6%	Wellington Management Group LLP	31 Oct 2025
MORGAN STANLEY	7.7%		$172,285,808		9,592,751		Morgan Stanley	31 Dec 2024
Deep Track Capital, LP	5.57%		$125,720,000		7,000,000		Deep Track Capital, LP	09 May 2025
BlackRock, Inc.	4.5%		$100,550,353		5,598,572		BlackRock, Inc.	31 Mar 2025
EcoR1 Capital, LLC	2.7%		$78,009,140		3,447,156		EcoR1 Capital, LLC	30 Sep 2025

Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	122,353,461	$2,771,618,915	-$154,804,544	$17,276,930	$92,843,010	$22.63	269
2025 Q2	131,608,288	$2,279,077,423	+$66,148,357	$10,697,634	$50,483,727	$17.31	246
2025 Q1	126,465,800	$2,767,959,579	-$78,248,319	$16,584,198	$20,020,131	$21.87	252
2024 Q4	126,723,891	$4,044,170,293	+$224,206,429	$26,788,232	$83,638,820	$31.91	259
2024 Q3	118,165,642	$3,408,098,233	-$32,772,311	$31,279,395	$110,070,555	$28.84	261
2024 Q2	115,428,997	$4,426,484,074	-$4,063,210	$26,288,108	$191,473,940	$38.36	259
2024 Q1	113,103,917	$6,646,510,438	-$27,789,991	$66,615,374	$73,398,586	$58.78	296
2023 Q4	113,568,311	$6,800,298,011	+$75,955,536	$96,362,628	$267,729,956	$59.86	278
2023 Q3	113,630,426	$4,326,001,749	-$249,890,323	$91,497,612	$247,215,396	$38.04	250
2023 Q2	106,464,737	$9,698,740,546	-$322,780,479	$120,015,982	$160,002,545	$91.1	311
2023 Q1	110,363,167	$7,278,027,538	+$671,099,429	$64,496,792	$98,722,556	$65.96	277
2022 Q4	100,652,525	$5,202,853,976	+$66,260,972	$37,024,360	$39,919,708	$51.71	239
2022 Q3	97,643,165	$6,665,378,163	+$32,228,664	$91,031,220	$42,702,000	$68.3	245
2022 Q2	91,648,969	$4,144,516,571	+$31,626,482	$10,817,000	$35,348,608	$45.22	205
2022 Q1	90,940,512	$4,620,842,334	+$520,061,489	$66,204,000	$59,064,284	$50.81	206
2021 Q4	81,021,271	$3,829,991,538	+$612,446,955	$19,044,000	$43,152,000	$47.28	183
2021 Q3	69,511,931	$2,291,947,609	-$95,194,645	$135,743,040	$119,417,528	$32.96	174
2021 Q2	64,601,991	$4,083,171,314	+$13,404,010	$89,211,720	$103,142,520	$63.2	201
2021 Q1	63,358,839	$2,718,377,161	+$19,912,136	$7,021,000	$17,726,000	$42.91	168
2020 Q4	63,890,305	$3,654,164,157	-$7,921,158	$6,612,000	$11,539,000	$57.2	165
2020 Q3	62,139,394	$1,874,756,231	+$24,663,304	$3,671,000	$7,651,000	$30.17	143
2020 Q2	61,184,997	$1,997,919,282	+$197,934,910	$5,987,000	$4,468,000	$32.66	141
2020 Q1	55,273,539	$1,482,076,889	+$294,686,642	$9,847,000	$3,151,000	$26.79	143
2019 Q4	43,885,493	$1,343,772,430	+$85,692,286	$31,095,000	$33,732,000	$30.62	132
2019 Q3	40,388,376	$973,049,791	+$46,440,436	$414,000	$9,002,000	$24.09	129
2019 Q2	40,468,785	$1,025,057,247	+$17,474,333	$1,901,000	$1,901,000	$25.34	99
2019 Q1	40,125,707	$782,326,949	+$160,534,739	$1,463,000	$1,463,000	$19.5	92
2018 Q4	32,104,592	$423,490,077	-$27,345,727			$13.19	95
2018 Q3	29,708,993	$528,224,019	+$9,616,309			$17.78	79
2018 Q2	29,064,186	$639,413,620	+$265,705,567			$22	73
2018 Q1	17,039,592	$375,355,107	+$8,764,830			$22.11	46
2017 Q4	15,746,683	$340,174,825	+$340,174,825			$21.7	46